Physician profile
Matthew Macey
NPI 1023428109
$11,017.62
in general payments reported to CMS, 2019-2025
44 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $1,045 · 2021: $1,679 · 2022: $2,253 · 2023: $2,012 · 2024: $2,219 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,373 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,373.20 |
| Education | $175.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $1,388.34 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $910.32 | 2019-2025 | Xtandi |
| Abbvie INC. | $850.87 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $836.99 | 2019-2025 | |
| Janssen Biotech, INC. | $768.49 | 2019-2025 | Erleada |
| Pfizer INC. | $710.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $512.50 | 2020-2025 | Lynparza, Imfinzi |
| Antares Pharma, INC. | $490.47 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Blue Earth Diagnostics | $479.77 | 2019-2025 | Posluma |
| Urogen Pharma, INC. | $465.26 | 2020-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $411.63 | 2023-2025 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $397.95 | 2019-2024 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $397.15 | 2022-2025 | Pylarify |
| Amgen INC. | $298.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $218.31 | 2022-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $183.39 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Bioprotect Medical, INC. | $155.98 | 2024 | Bioprotect Balloon Implant System |
| Endo USA, INC. | $155.67 | 2024-2025 | Xiaflex, Aveed |
| Neotract INC. | $126.38 | 2020 | |
| Accord Healthcare, INC. | $120.24 | 2023-2024 | |
| Urovant Sciences INC | $90.03 | 2021-2022 | |
| Ambu INC. | $88.01 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $83.06 | 2019-2025 | Yonsa |
| Ferring Pharmaceuticals INC. | $82.13 | 2024-2025 | Adstiladrin |
| Rochester Medical Corporation | $78.64 | 2020-2022 | |
| Myovant Sciences INC. | $76.33 | 2021-2022 | |
| Travere Therapeutics, INC. | $71.48 | 2019-2021 | |
| Foundation Medicine, INC. | $63.36 | 2020-2022 | |
| Teleflex LLC | $62.71 | 2021-2023 | Urolift |
| Tempus Ai, INC | $54.27 | 2024 | Xt Cdx |
| C. R. Bard, INC. & Subsidiaries | $48.32 | 2023 | Bard Urinary Drainage Bag |
| Mission Pharmacal Company | $41.21 | 2019-2020 | |
| Coloplast Corp | $38.20 | 2024 | |
| Halozyme INC | $34.16 | 2023 | |
| Photocure INC | $32.51 | 2019-2021 | |
| Tolmar, INC. | $30.00 | 2024 | |
| Myriad Genetic Laboratories, INC. | $25.83 | 2021 | |
| Clovis Oncology, INC. | $24.28 | 2020 | |
| Calyxo, INC. | $22.95 | 2024 | Cvac Aspiration System |
| Genzyme Corporation | $21.83 | 2023 | |
| Olympus America INC. | $21.65 | 2025 | Itind System |
| Cardinal Health 414 LLC | $18.89 | 2022 | |
| Axonics, INC. | $16.24 | 2023 | Axonics |
| Metuchen Pharmaceuticals | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Macey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.